ReNerve LimitedASX: RNV

First patient in India receives NervAlign Nerve Cuff

· Issued by ReNerve Limited via ASX

Filed with ASX · · 3 pages · English

Summary by 6ix AI

ReNerve Limited has announced that the first patient in India has received its NervAlign® Nerve Cuff, marking a significant step in the product's commercial use following regulatory approval. This milestone was achieved in partnership with NetCentrix Ventures, highlighting India's potential as a major market for nerve repair solutions due to its large population and high incidence of related injuries. The announcement follows record sales for the September quarter, indicating strong growth for the company as it expands its presence in the Asia-Pacific region.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

ASX Announcement 17 November 2026 First patient in India receives ReNerve’s NervAlign® Nerve Cuff Highlights • First patient in India treated with the NervAlign® Nerve Cu?, converting the Company’s CDSCO marketing 2 approval into clinical use • India is a major market opportunity for...

ReNerve Limited on 6ix

Story so far

Earlier from ReNerve

Later from ReNerve

All ReNerve news releases